Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial (Q30397511)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

phase II clinical trial

0 references

influenza vaccine

1 reference

based on heuristic

inferred from title

author name string

John J Treanor

1

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Laurence Chu

2

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Brandon Essink

3

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Derek Muse

4

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Hana M El Sahly

5

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Ruvim Izikson

6

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Karen L Goldenthal

7

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Peter Patriarca

8

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Lisa M Dunkle

9

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

language of work or name

0 references

publication date

11 January 2017

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

35

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

923-928

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

H5N1 influenza--continuing evolution and spread

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Some Methods for Strengthening the Common χ 2 Tests

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Tests for Linear Trends in Proportions and Frequencies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.12.053

7 January 2021

Identifiers

10.1016/J.VACCINE.2016.12.053

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30397511&oldid=1549822808"